«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:

2024年03期

页码:

175-180

栏目:

基础研究

出版日期:

2024-05-20

文章信息/Info

Title:

Study on the mechanism of shikonin regulating interleukin-6 in the treatment of pulmonary arterial hypertension

作者:

王勋; 左婉云; 肖政辉; 肖云彬; 陈智; 曾云红; 李文凤; 黄婷

410071 长沙，湖南省儿童医院心血管内科（王勋，肖云彬，陈智，曾云红），重症医学科（肖政辉），超声科 （李文凤，黄婷）；410011 长沙，中南大学湘雅二医院血液科（左婉云）

Author(s):

WANG Xun¹;  ZUO Wanyun²;  XIAO Zhenghui³;  XIAO Yunbin¹;  CHEN Zhi¹;  ZENG Yunhong¹;  LI Wenfeng⁴;  HUANG Ting⁴

1. Department of Cardiology, Hunan Children's Hospital, Changsha 410071; 2. Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha 410011; 3. Department of Intensive Care Unit, Hunan Children's Hospital, Changsha 410071;

关键词:

肺动脉高压; 紫草素; 白细胞介素6

Keywords:

Pulmonary arterial hypertension;  Shikonin;  Interleukin-6

分类号:

-

DOI:

10.3969/j.issn.1673-6583.2024.03.013

文献标识码:

-

摘要:

目的：探讨紫草素通过抑制白细胞介素（IL）-6 及其下游信号通路逆转肺动脉 高压（PAH）大鼠血流动力学和血管重构的机制。 方法：24 只SD 大鼠随机数字表法分 为对照组（CON 组）、野百合碱肺动脉高压组（MCT-PAH 组）、肺动脉高压紫草素干预组 （MCT-PAH＋SH 组），每组8 只。造模28 d 后检测各组大鼠肺动脉血流动力学、右室肥厚指 数，HE 染色鉴定肺动脉形态学变化，Western blot 和免疫组化检测IL-6、IL-21、CD163 等 分子的表达及定位。 结果：与CON 组相

Abstract:

Objective: Discuss whether shionin can reverse the changes of hemodynamic and vascular remodeling in animal models of PAH by regulating interleukin-6 and downstream signal pathways. Methods: Twenty-four SD rats were randomly divided into CON group, MCTPAH

参考文献/References

[1] Harbaum L, Rhodes CJ, Wharton J, et al. Mining the plasma proteome for insights into the molecular pathology of pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2022, 205(12):1449-1460.
[2] Wang RR, Yuan TY, Wang JM, et al. Immunity and inflammation in pulmonary arterial hypertension: from pathophysiology mechanisms to treatment perspective[J]. Pharmacol Res, 2022, 180:106238.
[3] Moutsoglou DM, Tatah J, Prisco SZ, et al. Pulmonary arterial hypertension patients have a proinflammatory gut microbiome and altered circulating microbial metabolites[J]. Am J Respir Crit Care Med, 2023, 207(6):740-756.
[4] Cai ZY, Li J, Zhuang Q, et al. MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-β1 and IL-6/STAT3 signaling pathways[J]. Exp Mol Med, 2018, 50(4):1-11.
[5] Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension[J]. Am J Respir Crit Care Med, 1995, 151(5):1628- 1631.
[6] Sun Q, Gong T, Liu ML, et al. Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches[J]. Phytomedicine, 2022, 94:153805.
[7] 代巧妹, 王金凤, 张凤山. 紫草素对晚期胶原性关节炎的作用 研究[J]. 哈尔滨医科大学学报, 2009, 43(1):48-51．
[8] Al-Qazazi R, Lima PDA, Prisco SZ, et al. Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2022, 206(5):608- 624.
[9] Hassoun PM. Pulmonary arterial hypertension[J]. N Engl J Med, 2021, 385(25):2361-2376.
[10] Hirsch K, Nolley S, Ralph DD, et al. Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension[J]. J Heart Lung Transplant, 2023, 42(2):173-182.
[11] Smits AJ, Botros L, Mol MAE, et al. A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension[J]. ERJ Open Res, 2022, 8(2):00009-2022.
[12] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1):2200879.
[13] Xu WL, Janocha AJ, Erzurum SC. Metabolism in pulmonary hypertension[J]. Annu Rev Physiol, 2021, 83:551-576.
[14] Paulin R, Courboulin A, Meloche J, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension[J]. Circulation, 2011, 123(11):1205-1215.
[15] Rose-John S. Interleukin-6 family cytokines[J]. Cold Spring Harb Perspect Biol, 2018,10(2):a028415.
[16] Awad KS, Elinoff JM, Wang SB, et al. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells[J]. Am J Physiol Lung Cell Mol Physiol, 2016, 310(2):L187-L201.
[17] Tangye SG, Ma CS. Regulation of the germinal center and humoral immunity by interleukin-21[J]. J Exp Med, 2020, 217(1):e20191638.
[18] Hashimoto-Kataoka T, Hosen N, Sonobe T, et al. Interleukin-6/ interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension[J]. Proc Natl Acad Sci U S A, 2015, 112(20):E2677-E2686.
[19] Troiano G, Caponio VCA, Adipietro I, et al. Prognostic significance of CD68＋ and CD163＋ tumor associated macrophages in head and neck squamous cell carcinoma: a systematic review and meta-analysis[J]. Oral Oncol, 2019, 93:66- 75.
[20] Jasiewicz M, Kowal K, Kowal-Bielecka O, et al. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension[J]. Cytokine, 2014, 66(1):40-45.
[21] Matsushita T, Takehara K. Soluble CD163 is a potential biomarker in systemic sclerosis[J]. Expert Rev Mol Diagn, 2019, 19(3):197-199.
[22] Guo CJ, He JL, Song XMI, et al. Pharmacological properties and derivatives of shikonin-a review in recent years[J]. Pharmacol Res, 2019, 149:104463.
[23] Fan C, Zhang XF, Upton Z. Anti-inflammatory effects of shikonin in human periodontal ligament cells[J]. Pharm Biol, 2018, 56(1):415-421.
[24] Guo HL, Sun JY, Li DY, et al. Shikonin attenuates acetaminophen-induced acute liver injury via inhibition of oxidative stress and inflammation[J]. Biomed Pharmacother, 2019, 112:108704.

备注/Memo

备注/Memo:

基金项目：国家自然科学基金（81500041）；湖南省卫生健康委课题（20200849）
通信作者：肖云彬， E-mail：xiaoyunbinrui@126.com

常用功能

更新日期/Last Update: 2024-05-20